Quarterly Report (10-q)

Date : 02/14/2017 @ 3:43PM
Source : Edgar (US Regulatory)
Stock : Gb Sciences, Inc. (QB) (GBLX)
Quote : 0.256  -0.004 (-1.54%) @ 4:30PM

Quarterly Report (10-q)


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
________________________
 
FORM 10-Q
__________________________
 
(Mark One)
ý
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________ to ___________

Commission file number:   000-55462

GB SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other Jurisdiction of Incorporation or organization)
 
59-3733133
(IRS Employer I.D. No.)
 
3550 W. Teco Avenue
Las Vegas, Nevada 89118
Phone: (866) 721-0297
(Address and telephone number of
principal executive offices)
 
N/A
(Former name, former address and former fiscal year, if changed since last report )
 
Indicate by check mark whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   ý   Yes        No
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    ý   Yes        No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer    
Accelerated filer        
Non-accelerated filer
(Do not check if a smaller Reporting Company)
Smaller reporting company   ý
 
 
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act).     Yes      ý   No  
 
There were 110,900,020 shares of common stock, par value $0.0001 per share, outstanding as of February 13, 2017 .
 

 
GROWBLOX SCIENCES, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2016

 
INDEX
 
Page
 
 
 
 
 
 
     
 
     
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
  21

 
 
PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements
 
GB SCIENCES, INC. AND SUBSIDIARIES
 
CONSOLIDATED CONDENSED BALANCE SHEETS
 
(unaudited)
 
   
   
   
31-Dec-16
   
31-Mar-16
 
CURRENT ASSETS:
           
      Cash and cash equivalents
 
$
991,325
   
$
34,824
 
      Accounts receivable
   
67,862
     
67,862
 
      Prepaid expenses
   
34,087
     
104,851
 
TOTAL CURRENT ASSETS
   
1,093,274
     
207,537
 
Property and Equipment, Net
   
7,683,982
     
1,953,048
 
Deposits and Prepayments
   
203,306
     
271,455
 
Other Assets
   
142,881
     
3,555
 
TOTAL ASSETS
 
$
9,123,443
   
$
2,435,595
 
CURRENT LIABILITIES:
               
Accounts Payable
 
$
126,432
   
$
902,123
 
Accrued Interest
   
143,492
     
61,786
 
Accrued Liabilities
   
370,006
     
834,348
 
Notes Payable, net of unamortized discount of $0.2 million and $0.4 million at December 31, 2016 and March 31, 2016, respectively
   
582,216
     
463,532
 
    TOTAL CURRENT LIABILITIES
   
1,222,146
     
2,261,789
 
Note Payable
   
473,250
     
2,148,556
 
Capital Lease Obligations
   
3,786,375
     
-
 
TOTAL LIABILITIES
   
5,481,771
     
4,410,345
 
Commitments and Contingencies (Note 7)
               
STOCKHOLDERS' (DEFICIT)/ EQUITY:
               
Common Stock Common Stock, $0.0001 par value, 200,000,000 shares authorized, 92,836,869 and 47,335,147 shares issued and outstanding at December 31, 2016 and March 31, 2016
   
9,284
     
4,733
 
Deferred Stock Compensation
   
2,332,327
     
2,240,662
 
Additional Paid In Capital
   
29,355,303
     
16,638,318
 
Accumulated Deficit
   
(28,112,414
)
   
(20,779,860
)
TOTAL GROWBLOX SCIENCES, INC. STOCKHOLDERS' (DEFICIT)/EQUITY
   
3,584,500
     
(1,896,147
)
Non-controlling interest
   
57,172
     
(78,603
)
TOTAL (DEFICIT)/EQUITY
   
3,641,672
     
(1,974,750
)
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)/EQUITY
 
$
9,123,443
   
$
2,435,595
 
 
               
The accompanying notes are an integral part of these condensed consolidated financial statements
 



GB SCIENCES, INC. AND SUBSIDIARIES
 
STATEMENTS OF OPERATIONS
 
(unaudited)
 
                         
 
                       
   
For the Three Months Ended December 31,
   
For the Nine Months Ended December 31,
 
   
2016
   
2015
   
2016
   
2015
 
                         
NET REVENUE
 
$
-
   
$
-
   
$
-
   
$
-
 
GENERAL AND ADMINISTRATIVE EXPENSES
   
3,215,104
     
1,128,837
     
6,637,764
     
5,344,747
 
LOSS FROM OPERATIONS
   
(3,215,104
)
   
(1,128,837
)
   
(6,637,764
)
   
(5,344,747
)
OTHER INCOME (EXPENSE)
                               
    Interest Expense
   
(290,153
)
   
(23,251
)
   
(746,614
)
   
(34,481
)
Other Income/(Expense)
   
(75,781
)
   
(2,747
)
   
(81,534
)
   
(2,512
)
Total other expense
   
(365,934
)
   
(25,998
)
   
(828,148
)
   
(36,993
)
NET LOSS
   
(3,581,038
)
   
(1,154,835
)
   
(7,465,912
)
   
(5,381,740
)
Net income/(loss) attributable to non-controlling interest
   
(56,658
)
   
(57,976
)
   
(133,520
)
   
(262,135
)
NET LOSS ATTRIBUTABLE TO GROWBLOX SCIENCES, INC.
 
$
(3,524,380
)
 
$
(1,096,859
)
 
$
(7,332,392
)
 
$
(5,119,605
)
  Net loss per share - basic and diluted
 
$
(0.04
)
 
$
(0.02
)
 
$
(0.11
)
 
$
(0.12
)
  Weighted average common shares outstanding - basic and diluted
   
88,836,452
     
46,388,156
     
68,954,306
     
44,354,340
 
 
                               
The accompanying notes are an integral part of these consolidated condensed financial statements
 

 

GB SCIENCES, INC. AND SUBSIDIARIES
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
(unaudited)
 
 
           
             
 
 
Nine Months Ended December 31,
 
   
2016
   
2015
 
OPERATING ACTIVITIES:
           
Net income (loss)
 
$
(7,465,912
)
 
$
(5,381,740
)
    Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation and amortization
   
251,599
     
132,680
 
Stock-based compensation
   
3,695,521
     
1,510,999
 
Amortization of debt discount and beneficial conversion feature
   
486,762
     
-
 
Loss on debt conversion
   
75,781
         
Loss on disposal
   
5,572
     
-
 
Changes in operating assets and liabilities:
               
Prepaid expenses and other assets
   
70,764
     
110,110
 
Accounts payable
   
12,186
     
619,153
 
Accrued expenses
   
26,433
     
146,737
 
Net cash used in operating activities
   
(2,841,294
)
   
(2,862,061
)
INVESTING ACTIVITIES:
               
Purchase of property and equipment
   
(1,929,375
)
   
(881,595
)
Change in deposits
   
(74,227
)
   
52,699
 
Net cash used in investing activities
   
(2,003,602
)
   
(828,896
)
FINANCING ACTIVITIES:
               
Proceeds from issuance of common stock and warrants
   
5,140,179
     
1,377,848
 
Proceeds from non-controlling interest
   
269,296
     
350,000
 
Proceeds from convertible notes
   
654,805
     
1,754,872
 
Payments under long-term obligations
   
(261,854
)
   
-
 
Cash used to purchase warrants
   
-
     
(56,000
)
Other financing activities
   
(1,029
)
   
330,903
 
   Net cash provided by financing activities
   
5,801,397
     
3,757,623
 
Net change in cash and cash equivalent
   
956,501
     
66,666
 
CASH AND CASH EQUIVALENT AT BEGINNING OF PERIOD
   
34,824
     
-
 
CASH AND CASH EQUIVALENT AT END OF PERIOD
 
$
991,325
   
$
66,666
 
Non-cash transactions:
               
Stock issued to settle payables
 
$
590,777
   
$
377,824
 
Stock issued to upon conversion of long-term note payable
 
$
2,576,750
   
$
-
 
Stock issued to settle legal obligations
 
$
460,840
   
$
-
 
Capital lease obligation
 
$
3,900,000
   
$
-
 
Stock and warrants issued upon amendment of long-term note payable
 
$
875,663
   
$
-
 
 
               
The accompanying notes are an integral part of these consolidated condensed financial statements
 

 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 1 – Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the "Company," "We" or "Us") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulations S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.  Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2017. The balance sheet at March 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the year ended March 31, 2016.
Principles of Consolidation
The condensed consolidated financial statements include all operating divisions and majority owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Reclassifications
Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation.  These reclassifications had no effect on the reported financial position, results of operations or cash flows of the entity.
Significant Accounting Policies
A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2016.
Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board ("FASB") issued amended accounting guidance that changes the accounting for leases and requires expanded disclosures about leasing activities. Under the new guidance, lessees will be required to recognize a right-of-use asset and a lease liability, measured on a discounted basis, at the commencement date for all leases with terms greater than twelve months. Lessor accounting will remain largely unchanged, other than certain targeted improvements intended to align lessor accounting with the lessee accounting model and with the updated revenue recognition guidance issued in 2014. Lessees and lessors must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The amended guidance is effective for annual reporting periods (including interim periods within those periods) beginning after December 15, 2018, and early application is permitted. The Company is currently evaluating the impact this guidance will have on its financial position and results of operations.

Management does not believe that any other recently issued but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Note 2 – Going Concern
The Company's condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of approximately $28.1 million at December 31, 2016. In addition, the Company has consumed cash in its operating activities of approximately $2.8 million for the nine months ended December 31, 2016 compared to $2.9 million for the same period last year. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.
Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing.  There are no assurances that the Company will be successful in achieving its goals.
In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.
Note 3 – Convertible Notes

In February 2016, the Company issued a short-term Promissory Note ("Note") with a face value of $192,500 resulting in aggregate proceeds of $175,000 reflecting a 9.1% original discount and a nominal rate of 10%. The Note is payable within one year of issuance and is convertible into 962,500 shares of the Company's common stock and 962,500 common stock purchase warrants at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.50 per share for a period of three years.  The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $94,037 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and the Note. In addition to this discount related to the beneficial conversion feature, an additional discount of $66,912 was recorded based on the fair value of the 962,500 warrants attached to the Note. This value was derived using the Black-Scholes valuation model. At December 31, 2016, the Note had a balance of $0.2 million net of $0.01 million unamortized discount and beneficial conversion feature.
In March 2016, the Company issued a short-term Promissory Note ("Note") with a face value of $300,000 resulting in aggregate proceeds of $250,000 reflecting a 16.67% original discount and a nominal rate of 20%. The Note is payable within one year of issuance and is convertible into 1,500,000 shares of the Company's common stock and 1,500,000 common stock to purchase warrants at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.50 per share for a period of three years. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $143,750 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the attached warrants and the Note. In addition to this discount related to the beneficial conversion feature, an additional discount of $93,750 was recorded based on the fair value of the 1,500,000 warrants attached to the Note.
On November 7, 2016, the Company received a notice that the Noteholder had elected to convert its $300,000 Note into common stock of the Company pursuant to the Short-Term Convertible Note Agreement.  Accordingly, the Company issued 1,500,000 shares of its common stock ($300,000 converted at a price of $0.20 per share) and a warrant to purchase 1,500,000 shares of the Company's common stock at the price of $0.50 per share for the period of three years.  As a result of the conversion, the Company recorded a loss of $0.1 million.
In July 2016, the Company issued a short-term Promissory Note ("Note") resulting in aggregate proceeds of $500,000. The Note is payable within one year of issuance and is convertible into 2,500,000 shares of the Company's common stock at any time and from time to time before maturity at the option of the holder. The beneficial conversion feature resulting from the discounted conversion price compared to the market price was calculated based on the date of issuance to be $350,000 after adjusting the effective conversion price for the relative fair value of the note proceeds compared to the fair value of the Note. At December 31, 2016, the Note had a balance of $0.3 million net of $0.2 million unamortized beneficial conversion feature.
The Notes and Warrants were issued in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933 (the " Securities Act ") and/or Rule 506 of Regulation D under the Securities Act, as amended.

Note 4– Note Payable
The Company entered into a Note Purchase Agreement, dated May 12, 2015 and effective as of June 8, 2015, with Pacific Leaf Ventures, LP ("Pacific Leaf"), pursuant to which Pacific Leaf has made installment loans (the "Loans") to the Company in the aggregate amount of $1.75 million. The purpose of the financing is to provide for the acquisition and installation of an operating facility, equipment and other tangible assets by GB Sciences Nevada, LLC ("GBSN"). Such facility and equipment was dedicated to the cultivation of cannabis and the extraction of oils and other constituents present in cannabis, subject at all times to Nevada legal requirements. The note is convertible at the option of the holder into common shares at a conversion price of $0.50, subject to anti-dilution adjustments.
To evidence the Loans, the Company issued to Pacific Leaf a 6% senior secured convertible promissory note (the "Note"), bearing interest at the rate of 6% per annum, payable quarterly. All outstanding principal and interest due under the Note were due and payable on May 12, 2020. The Company was required to prepay the outstanding principal amount of the Note on a quarterly basis in an amount equal to 50% of the cash flow (accrued EBITDA) of GBSN attributable to our percentage interest in GBSN no later than the earlier to occur of (a) the fifth (5th) business day following receipt of a distribution of the Company's Share of GBSN's EBITDA for the calendar quarter in question, or (b) thirty (30) days following the end of the calendar quarter in question, with the first such prepayment to be made not later than July 31, 2015 with respect to the quarter ending June 30, 2015. In order to induce the Pacific Leaf to extend the loan to the Company and to secure the payment and performance of all of the Secured Obligations, the Company agreed to grant Pacific Leaf a security interest in certain of its assets and enter into the lending agreement.
On February 8, 2016, the Company entered into the Amended and Restated 6% Senior Convertible Promissory Note ("Amended Note") with Pacific Leaf.  The amended agreement modifies the 6% Senior Secure Convertible Promissory Note dated May 12, 2015 and effective as of June 8, 2015, in the principal amount of $1.75 million.
Per the terms of the amended agreement, Pacific Leaf may make up to $1.0 million in additional advances to the Company under the Amended Note bringing the total in the aggregate to $2.75 million. The note is convertible at the option of the holder into common shares at a conversion price of $0.25, subject to anti-dilution adjustments. The Company has an option to prepay the Amended Note, without premium or penalty, in whole or in part, with accrued interest to the date of such prepayment.
Until the payment in full of the Amended Note, the Pacific Leaf or its designee have the option (the "Option") to purchase up to a 20% membership interest in GBSN for a purchase price equal to $100,000 for each 2% of membership interest purchased (i.e., $1,000,000 if the Option is exercised in full), provided that the Option may not be exercised for less than a 1% membership interest in GBSN.
In connection with the Amended Note, the Company also entered into the Amended and Restated Royalty Agreement with Pacific Leaf dated and effective as of February 8, 2016.  Per the terms of the Amended Royalty Agreement, the royalty rate at any time shall equal to the sum of (i) 9.1%, and (ii) the percentage calculated by dividing the amount advanced in excess of $1.75 million by $1.0 million, multiplied by the gross revenues of GBSN.  On the earlier of (i) the seventh anniversary of the royalty payment date, or (ii) the date that all amounts outstanding under the Amended Note have been paid in full, the royalty rate shall be reduced by 50%.
On June 13, 2016, the Company received notice from the Pacific Leaf that it had elected to convert $500,000 of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory.  Accordingly, the Company has issued 2,000,000 shares of its common stock ($500,000 converted at a price of $0.25 per share) to Pacific Leaf and the Company's indebtedness pursuant to the Note was reduced by $500,000.
On August 4, 2016, the Company entered into the Second Omnibus Amendment ("Second Amendment") of its existing agreements with Pacific Leaf.  The Second Amendment eliminates Pacific Leaf's option to purchase up to a 20% membership interest in GBSN and reduces Pacific Leaf's existing royalty rate to 16.4% of the gross sales revenue of GBSN.  It also caps maximum aggregate royalty payments to be made to Pacific Leaf at $2,420,000 with respect to any calendar year. In consideration of the amended terms, Pacific Leaf and its designees received 1,000,000 shares of the Company's common stock and a five-year warrant to purchase 1,500,000 shares of the Company's common stock at $0.36 per share resulting in related expense of approximately $0.9 million.
On October 4, October 20, November 1, and November 10, 2016, the Company received notices the Pacific Leaf that it had elected to convert total of $1,776,750 of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory.  Accordingly, the Company has issued 7,107,000 shares of its common stock ($1,776,750 converted at a price of $0.25 per share) to Pacific Leaf and the Company's indebtedness pursuant to the Note has been reduced by $1,776,750. As of December 31, 2016, the total amount of installments received, net of conversion, is $0.5 million.
Note 5 – Capital Lease
In July, 2016, an entity associated with Pacific Leaf Partners, LLC completed the purchase of the building housing the Company's cultivation facility at 3550 W. Teco Ave., Las Vegas, NV. In connection with the purchase, the Company entered into the Amended Lease Agreement for an initial term of ten and a half years with one option to extend the lease for five years, or until December 31, 2030. The monthly rent payments per the Amended Lease Agreement are $40,000 through December 31, 2017. Commencing January 1, 2018, the monthly rent payments will increase by 3% per annum through the expiration of the lease. The Company analyzed the transaction in accordance with the applicable accounting guidance determining that the aggregate amount of $3.9 million met the requirements for capitalization. The building has been capitalized and is included in property and equipment, net balance with related obligations included as part of current and non-current liabilities. The obligation recorded is based upon the present value of the future minimum lease payment discounted at 11.6% interest rate. 
Note 6 – Capital Transactions
During the nine months ended December 31, 2016, the Company issued an aggregate of 1,991,943 shares of common stock in settlement and release of certain obligations owed by the Company to various persons and recorded related expenses of $0.6 million, as follows:

·
The Company issued 512,275 shares of its common stock in connection with the conversion of $0.2 million in indebtedness owed by us to various persons at a conversion price of approximately $0.38 per share.

·
The Company issued 323,692 shares of common stock in connection with settlement of payroll liabilities owed by us to our executives at a conversion price of $0.19 per share. The Company recorded approximately $0.1 million of compensation expense.

·
The Company issued 1,017,087 shares of its common stock in connection with the conversion of $0.3 million in indebtedness owed by us to various persons at a conversion price of approximately $0.33 per share.
 
·
The Company issued 138,889 shares of its common stock at a conversion price of $0.36 per shares in connection with a settlement of certain legal obligations owed by us. The Company recorded approximately $0.05 million of compensation expense.
 
·
On April 8, 2016, the Company issued 200,000 of its common shares to its former Chief Financial Officer, in exchange for a full dismissal with prejudice of all causes of action pending in the complaint filed against the Company on August 19, 2015. The Company recorded approximately $0.04 million of legal settlement expense.

 

·
During the nine months ended December 31, 2016, the Company received notice from Pacific Leaf Ventures, LP ("Pacific Leaf") that it had elected to convert $2,276,750 of the Company's indebtedness to Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory.  Accordingly, the Company has issued 9,107,000 shares of its common stock ($2,276,750 converted at a price of $0.25 per share) to Pacific Leaf.
 
·
On August 9, 2016, the Company finalized a settlement agreement in final disposition of the lawsuit filed by the Company on April 2, 2014, in the United States District Court for the Southern District of New York.  The suit is more particularly described in Part I, Item 3 of the Company's Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on July 14, 2016.  The Company issued 1,400,000 shares of restricted common stock to certain non-affiliates of the Company and recorded a related expense of $0.4 million.

During the nine months ended December 31, 2016, The Company issued 763,612 shares in exchange for consulting services and recorded a related expense of $0.3 million. The Company also issued 116,667 shares of common stock to employees and recorded an expense of $0.04 million.

On August 4, 2016, Company issued 1,000,000 shares to Pacific Leaf and its designees and recorded a related expense of $0.4 million. The common shares were issued to satisfy the conditions under the Second Omnibus Amendment described in detail in Note 4 to the financial statements for the nine months ended December 31, 2016

During nine months ended December 31, 2016, the Company sold 14,847,500 units through a private placement at a price of $0.20 per unit.  Each unit consisted of one share of common stock and one common stock purchase warrant, expiring in three years, with an exercise price of $0.50. The Company also sold 15,000,000 units through a private placement at a price of $0.20 per unit.  Each unit consisted of one share of common stock and one common stock purchase warrant, expiring in five years, with an exercise price of $0.60. Lastly, the Company sold 25,000 shares of common stock to an independent party at the price of $0.51 per share. The Company recorded net proceeds of $5.1 million as a result of these issuances.

Options and Warrants
On June 1, 2016, the Company issued 900,000 stock options under the 2014 Equity Incentive Plan to the independent members of the Company's Board of Directors. The options are exercisable upon vesting for a period of 7 years from issuance at an exercise price of $0.16 per share. The Company has recognized total of $0.1 million in share-based compensation expense related to options vested to date.

On June 1, 2016, the Company issued 1,400,000 stock options under the 2014 Equity Incentive plan to its Chief Executive Officer. The options are exercisable upon vesting for a period of 7 years from issuance at an exercise price of $0.30 per share. The Company has recognized total of $0.2 million in share-based compensation expense related to options vested to date.

Effective on June 1, 2016, the Company amended its employment agreement with its Chief Science Officer, Andrea Small-Howard.  Pursuant to the amendment, Dr. Small-Howard surrendered a stock award for 450,000 shares of common stock in exchange for warrants to purchase 1,200,000 common shares at the strike price of $0.30 per share. The Company has recognized total of $0.1 million in share-based compensation expense related to warrants vested to date.

During the nine months ended December 31, 2016, the Company issued 1,500,000 stock options under the 2014 Equity Incentive Plan to various employees. The options are exercisable upon vesting for a period of 10 years from issuance at an exercise price ranging from $0.30 to $0.40 per share. The Company has recognized total of $0.1 million in share-based compensation expense related to options vested to date.

On August 4, 2016, Company issued a warrant to purchase 1,150,000 shares of the Company's common stock at the price of $0.36 per share to Pacific Leaf and its designees and recorded a related expense of $0.5 million. The warrant to purchase common shares was issued to satisfy the conditions under the Second Omnibus Amendment described in detail in Note 4 to the financial statements for the nine months ended December 31, 2016.

On November 7, 2016, the Company received a notice that the Noteholder had elected to convert $300,000 of the Company's indebtedness into common stock of the Company pursuant to the Short-Term Convertible Note Agreement.  Accordingly, the Company issued 1,500,000 shares of its common stock ($300,000 converted at a price of $0.20 per share) and a warrant to purchase 1,500,000 shares of the Company's common stock at the price of $0.50 per share for the period of three years.  As a result of the conversion, the Company recorded a loss of $0.1 million.
During the nine months ended December 31, 2016, the Company issued a compensation warrant to purchase 1,912,500 shares of the Company's common stock pursuant to the terms of a private placement agreement. The warrant is exercisable at the price of $0.50 per share for the period of three years. As a result of this issuance, the Company recorded compensation expense of $0.9 million.
During the nine months ended December 31, 2016, the Company issued a compensation warrant to purchase 1,500,000 shares of the Company's common stock pursuant to the terms of a private placement agreement. The warrant is exercisable at the price of $0.60 per share for the period of five years. As a result of this issuance, the Company recorded compensation expense of $0.4 million.
All of the foregoing securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 (the " Securities Act ") and/or Rule 506 of Regulation D under the Securities Act, as amended.

Note 7 – Commitments and Contingencies
Growblox Sciences, Inc.  v. GCM Administrative Services, LLC

On August 9, 2016, the Company finalized a settlement agreement in final disposition of the lawsuit filed by the Company on April 2, 2014, in the United States District Court for the Southern District of New York.  The suit is more particularly described in Part I, Item 3 of the Company's Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on July 14, 2016.  The Company issued 1,400,000 shares of restricted common stock to certain non-affiliates of the Company and recorded a related expense of $0.4 million

Cathryn Kennedy Complaint Settlement
On August 19, 2015, Cathryn Kennedy, our former Chief Financial Officer, filed a Complaint against us in the District Court in Clark County, Nevada alleging that she was assigned new duties by us which constituted a termination without cause effective July 24, 2015, and that as a consequence thereof she is entitled to severance, vacation pay and stock compensation from us pursuant to her Employment Agreement dated November 18, 2014.  On April 8, 2016, the Company entered into a mutual agreement with Cathryn Kennedy per terms of which the Company issued 200,000 of its unrestricted common shares valued at $40,000 in exchange for a full dismissal with prejudice of all causes of action pending in the above-referenced Complaint.
From time to time, the Company also becomes involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.
Note 8 – Loss per Share
The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 56,581, 664 and 27,558,334 of potentially dilutive common shares at December 31, 2016 and March 31, 2016, respectively.  However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.
Note 9 – Subsequent Events
Pacific Leaf Note Conversion Notice
On January 24, 2017, the Company received notices from Pacific Leaf Ventures, LP ("Pacific Leaf") that it had elected to convert $338,083 ($242,938 in principal and $95,145 in accrued interest) of the Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory.  Accordingly, the Company has issued 1,352,332 shares of its common stock ($338,083 converted at a price of $0.25 per share) to Pacific Leaf. Of the amount converted, $242,938 related to Note's principal and $95,145 related to accrued interest.
Short-Term Note Conversion
On January 25, 2017, the Company received a notice from the Holder of the Short-Term Promissory Note ("Note") issued in July 2016 with face value of $500,000. The Holder had elected to convert $500,000 of the Company's indebtedness into common stock of the Company pursuant to the Convertible Note Agreement. Accordingly, the Company had issued 2,500,000 shares of its common stock ($500,000 converted at a price of $0.20 per share).
Discounting of Warrants
In order to encourage the exercise of the 15,512,500 warrants issued to investors in private offering dated December 2, 2015 and the 15,000,000 warrants issued to investors in private offering dated August 26, 2016, the Company effected a decrease in the exercise price of the warrants from $0.50 and $0.60, respectfully, to $0.20 per share . As a result of the price reduction, total of 13,985,500 warrants were exercised as of the date of the filing of the Form 10-Q for the period ended December 31, 2016 .
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis contains "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "could", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts" or "continue" , which list is not meant to be all-inclusive and other such negative terms and comparable technology.  These forward-looking statements, include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements.  The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include among other things: (1)product demand, market and customer acceptance of Growblox Sciences products, equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified personnel, (iv)competition pricing and development difficulties, (v) general industry and market conditions and growth rates, unexpected natural disasters, and other factors, which we have little or no control: and other factors discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this report.
The following discussion highlights the Company's results of operations and the principal factors that have affected our financial condition, as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis is based on the Company's unaudited financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read this discussion and analysis together with such financial statements and the related notes thereto.
Overview
The Company seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.
Although we believe that maximum shareholder value will ultimately be achieved through the development, production and marketing of certified cannabinoid medicines, therapies and treatments, in order to generate cash flow and near term profitability, we intend to cultivate and dispense cannabis for medical purposes in both Nevada and other states which permit such sales and in which we and our operating partners are able to obtain cultivation and dispensing licenses.
We seek to become a trusted producer of consistent and efficacious medicinal strains and products, combining both cannabinoids and terpenes, which we intend to market in those states within the United States and in other countries where the sale of medical cannabis products are permitted. In addition, subject to obtaining Food and Drug Administrative (FDA) certification, we intend to market our cannabinoid-based drug discoveries on a world-wide basis.
We were incorporated in the State of Delaware on April 4, 2001, under the name "Flagstick Venture, Inc." On March 28, 2008, stockholders owning a majority of our outstanding common stock approved changing our then name "Signature Exploration and Production Corp." as our business model had changed.

On March 13, 2014, we entered into a definitive assets purchase agreement for the acquisition of assets, including the Growblox™ cultivation technology which resulted in a change in our corporate name on April 4, 2014, from Signature Exploration and Production Corporation to Growblox Sciences, Inc.

Effective December 12, 2016, the Company amended its Certificate of Corporation pursuant to shareholder approval as reported in the Form 8-K filed on October 14, 2016.  Pursuant to the amendment the Company's name was changed from Growblox Sciences, Inc. to GB Sciences, Inc.

Plan of Operation
The Company is cultivating cannabis using innovative, but conventional methods in its wholly owned subsidiary, GB Sciences Nevada, LLC ("GBSN"). On January 4, 2017, GBSN received a State Registration Certificate ("Certificate") for its 28,000-sq. ft. cannabis cultivation facility located in Las Vegas, NV. The receipt of the Certificate allows the Company to cultivate medical cannabis. Phase 1 of the GBSN cultivation facility opened with 200 grow lights. When all phases of construction are completed, the facility is expected to produce 6,800 pounds of marijuana per year and generate revenues of $16.9 million, based on a projected wholesale price of $2,500 per pound.  Completion of all Phases of this facility is dependent upon the availability of capital to complete construction. The Company has made completion of all Phases of this facility its number one priority.

On October 4, 2016, we acquired a 60% interest in a Nevada Medical Marijuana Production License with an option of up to 80%.  A production license enables us to convert cannabis plants into to oils and extracts that are suitable for creating medical compounds as well as consumer products. This license is critical and essential to our plan of producing cannabis-based medicines, and must be integrated into our cultivation facility to ensure quality control standards and efficiency in our production of cannabis medicines.

We expect our products to compete well in the marketplace because of the considerable efforts we have made in the plant genetics and tissue culturing of our proprietary strains of cannabis.  And, we are the exclusive Nevada grower of Kyle Kushman's proprietary marijuana strains which have been highly rated top sellers in California.

The current emphasis on near-term cash flow allows us to plan for exploiting the potential of our science assets.  We recently formed Growblox Life Sciences, LLC and have retained Fenwick & West, a Silicon Valley based law firm focusing on life sciences and high technology companies with a nationally top-ranked intellectual property practice, to development strategies for the protection of the Company's intellectual property. On October 11, 2016 we filed the first of several planned patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC.  The current provisional patent application covers complex-cannabinoid-containing mixtures capable of enhancing dopamine secretion and protecting neurons from the mitochondria-induced free radical damage that occurs during disease progression in the brains of patients with Parkinson's disease, Alzheimer's disease, Lewy Body Dementia, and Huntington's disease, among others. At this time, the Company plans to seek partners in the pharmaceutical industry or alternatively venture funding to advance these cannabis-based formulations to clinical testing and commercialization.

On December 13, 2016, Growblox Life Sciences, LLC licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of potentially new therapeutic agents for the treatment of cardiac hypertrophy and heart failure. Licensing this TRPV1 patent underscores the Company's drug discovery commitment to targeting the non-classical cannabinoid receptors, beyond the usual CB1 and CB2 receptors.
 
RESULTS OF OPERATIONS
The following table sets forth certain of our Statements of Operations data:
   
For the Three Months Ended December 31,
   
For the Nine Months Ended December 31,
 
   
2016
   
2015
   
2016
   
2015
 
                         
Revenue
 
$
-
   
$
-
   
$
-
   
$
-
 
General and administrative expenses
   
3,215,104
     
1,128,837
     
6,637,764
     
5,344,747
 
Other Expense
   
(365,934
)
   
(25,998
)
   
(828,148
)
   
(36,993
)
Net loss attributable to non-controlling interest
   
(56,658
)
   
(57,976
)
   
(133,520
)
   
(262,135
)
Net Loss
 
$
(3,524,380
)
 
$
(1,096,859
)
 
$
(7,332,392
)
 
$
(5,119,605
)

Comparison of the Three Months Ended December 31, 2016 and 2015
Revenues
The Company has not achieved any operating revenues to date.
General and administrative expenses
General and administrative expenses increased $2.1 million to $3.2 million for the three months ended December 31, 2016 compared to $1.1 million for the three months ended December 31, 2015. The increase in primarily attributable to a $1.3 million increase in share-based compensation expense related to an issuance of  a compensation warrant to purchase 3,412,500 shares of the Company's common stock pursuant to the terms of a private placement agreement. This increase is combined with a $0.7 million increase in consulting and advisory services.
Other expense
Total other expense increased by $0.3 million compared to the same period in prior year. The increase in primarily due to amortization of the debt discount related to the beneficial conversion features discount recorded on the convertible debt.
Comparison of the Nine Months Ended December 31, 2016 and 2015
Revenues
The Company has not achieved any operating revenues to date.
General and administrative expenses
General and administrative expenses increased $1.3 million to $6.6 million for the nine months ended December 31, 2016 compared to $5.3 million for the nine months ended December 31, 2015. The increase in primarily attributable to a $1.3 million increase in share-based compensation expense related to an issuance of  a compensation warrant to purchase 3,412,500 shares of the Company's common stock pursuant to the terms of a private placement agreement.
Other expense
Total other expense increased by $0.8 million compared to the same period in prior year. The increase in primarily due to $0.7 million amortization of the debt discount related to the beneficial conversion features discount recorded on the convertible debt and the recognition of $0.1 million in accrued interest related to the Pacific Leaf Loan.

LIQUIDITY AND CAPITAL RESOURCES
Current Liquidity
The Company will need additional capital to implement our strategies. There is no assurance that it will be able to raise the amount of capital needed for future growth plans. Even if financing is available, it may not be on terms that are acceptable. If unable to raise the necessary capital at the times required, the Company may have to materially change the business plan, including delaying implementation of aspects of the business plan or curtailing or abandoning the business plan. The Company represents a speculative investment and investors may lose all of their investment. In order to be able to achieve the strategic goals, the Company needs to further expand its business and financing activities. Based upon the cash position, it is necessary to raise additional capital by the end of the next quarter in order to continue to fund current operations. These factors raise substantial doubt about the ability to continue as a going concern.  The Company is pursuing several alternatives to address this situation, including the raising of additional funding through equity or debt financings. In order to finance existing operations and pay current liabilities over the next twelve months, the Company will need to raise approximately $4-5 million of capital depending upon license status. No assurance can be given that the Company will be able to operate profitably on a consistent basis, or at all, in the future.
The principal sources of liquidity to date have been cash generated from sales of debt and equity securities and loans.
At December 31, 2016, cash was $1 million, other current assets excluding cash were $0.1 million, and our working capital deficit was $0.1 million. At the same time, current liabilities were approximately $1.2 million, which consisted principally of $0.6 million in notes payable and $0.4 million in accrued liabilities. At March 31, 2016, the Company had cash balance $0.03 million, other current assets excluding cash were $0.2 million and our working capital deficit was $2.1 million. Current liabilities were approximately $2.3 million, which consisted principally of $0.9 million in accounts payable, $0.8 million in accrued liabilities, and $0.5 million in notes payable. An improvement in our liquidity position at December 31, 2016 compared to March 31, 2016 is primarily attributable to the capital raised through private offerings.
Sources and Uses of Cash
Operating Activities
Net cash used in operating activities was $2.8 million for the nine months ended December 31, 2016, as compared to net cash used of $2.9 million for the nine months ended December 31, 2015. We anticipate that cash flows from operations may be insufficient to fund business operations for the next twelve-month period. Accordingly, we will have to generate additional liquidity or cash flow to fund our current and anticipated operations. This will likely require the sale of additional common stock or other securities. There is no assurance that we will be able to realize any significant proceeds from such sales, if at all.

Investing Activities

During the nine months ended December 31, 2016 and 2015, the Company used $2 million and $0.8 million, respectively, of cash in investing activities. The cash used in investing activities during the nine months ended December 31, 2016 and 2015 was primarily for the purchase of property and equipment.

Financing Activities

During the nine months ended December 31, 2016 and 2015, cash flows from financing activities totaled $5.8 million and $3.8 million, respectively. Cash flows from financing activities for the nine months ended December 31, 2016 related primarily to $5.1 million in proceeds from the issuance of common stock and warrants, $0.7 million in proceeds from convertible notes, and $0.3 million in proceeds from non-controlling interests. Cash flows from financing activities for the nine months ended December 31, 2015 related primarily to $1.4 million in proceeds from the issuance of common stock and warrants, $1.8 million in proceeds from notes payable, and $0.4 million in proceeds from non-controlling interests.

GOING CONCERN

The unaudited interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize assets and discharge liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of approximately $28.1 million as of December 31, 2016, and further losses are anticipated in the development of the business raising substantial doubt about the ability to continue as a going concern. The ability to continue as a going concern is dependent upon generating profitable operations in the future and/or obtaining the necessary financing to meet obligations and repay liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and/or private placements of debt and equity securities. The financials do not include any adjustments relating to the recoverability and reclassification of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.
VARIABLES AND TRENDS
In the event the Company is able to obtain the necessary financing to progress with its business plan, the Company expects expenses to increase significantly to grow the business. Accordingly, the comparison of the financial data for the periods presented may not be a meaningful indicator of future performance and must be considered in light of these circumstances.
CRITICAL ACCOUNTING POLICIES
A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2016.
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.
ITEM 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company  maintains disclosure controls and procedures that are designed to ensure that material information required to be disclosed in the periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. At the end of the quarter ended December 31, 2016, the Company carried out an evaluation, under the supervision and with the participation of management, including the principal executive officer and the principal financial officer, of the effectiveness of the design and operation of disclosure controls and procedures, as defined in Rule 13(a)-15(e) and Rule 15d-15(e) under the 1934 Act. Based on this evaluation, management concluded that as of December 31, 2016 the disclosure controls and procedures were not effective due to material weaknesses as no member of our board of directors qualifies as an "audit committee financial expert" as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act.
Limitations on Effectiveness of Controls and Procedures
Management, including the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Controls
During the fiscal quarter ended December 31, 2016, there have been no changes in the internal controls over financial reporting that have materially affected or are reasonably likely to materially affect the internal controls over financial reporting. 
PART II – OTHER INFORMATION
ITEM 1. Legal Proceedings
From time to time, the Company also becomes involved in certain legal proceedings and claims which arise in the ordinary course of business. In our opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, we will record a reserve for the claim in question. If and when we record such a reserve is recorded, it could be material and could adversely impact our results of operations, financial condition, and cash flows.
ITEM 1A. Risk Factors
There are no material changes from the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the SEC.
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
Common Stock
During the nine months ended December 31, 2016, the Company received notice from Pacific Leaf Ventures, LP ("Pacific Leaf") that it had elected to convert $2,276,750 of the Company's indebtedness to Pacific Leaf Note into common stock of the Company pursuant to the Amended and Restated 6% Senior Secured Convertible Promissory.  Accordingly, the Company has issued 9,107,000 shares of its common stock ($2,276,750 converted at a price of $0.25 per share) to Pacific Leaf.

On August 4, 2016, Company issued 1,000,000 shares to Pacific Leaf and its designees and recorded a related expense of $0.4 million. The common shares were issued to satisfy the conditions under the Second Omnibus Amendment described in detail in Note 4 to the financial statements for the nine months ended December 31, 2016.

On August 9, 2016, the Company finalized a settlement agreement in final disposition of the lawsuit filed by the Company on April 2, 2014, in the United States District Court for the Southern District of New York.  The suit is more particularly described in Part I, Item 3 of the Company's Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission on July 14, 2016.  The Company issued 1,400,000 shares of restricted common stock to certain non-affiliates of the Company and recorded a related expense of $0.4 million.

During nine months ended December 31, 2016, the Company sold 14,847,500 units through a private placement at a price of $0.20 per unit.  Each unit consisted of one share of common stock and one common stock purchase warrant, expiring in three years, with an exercise price of $0.50. The Company also sold 15,000,000 units through a private placement at a price of $0.20 per unit.  Each unit consisted of one share of common stock and one common stock purchase warrant, expiring in five years, with an exercise price of $0.60. Lastly, the Company sold 25,000 shares of common stock to an independent party at the price of $0.51 per share. The Company recorded net proceeds of $5.1 million as a result of these issuances.

Options and Warrants
On June 1, 2016, we issued 900,000 stock options under our 2014 Equity Incentive Plan to the independent members of the Company's Board of Directors. The options are exercisable upon vesting for a period of 7 years from issuance at an exercise price of $0.16 per share. As of December 31, 2016, the Company recognized total of $0.1 million in share-based compensation expense related to options vested to date.

On June 1, 2016, we issued 1,400,000 stock options under our 2014 Equity Incentive plan to our Chief Executive Officer. The options are exercisable upon vesting for a period of 7 years from issuance at an exercise price of $0.30 per share. As of December 31, 2016, the Company recognized total of $0.2 million in share-based compensation expense related to options vested to date.

Effective on June 1, 2016, the Company amended its employment agreement with its Chief Science Officer, Andrea Small-Howard.  Pursuant to the amendment, Dr. Small-Howard surrendered a stock award for 450,000 shares of common stock in exchange for warrants to purchase 1,200,000 common shares at the strike price of $0.30 per share. As of December 31, 2016, the Company recognized total of $0.1 million in share-based compensation expense related to warrants vested to date.

During the nine months ended December 31, 2016, we issued 1,150,000 stock options under our 2014 Equity Incentive Plan to various employees. The options are exercisable upon vesting for a period of 10 years from issuance at an exercise price ranging from $0.30 to $0.40 per share. As of December 31, 2016, the Company recognized total of $0.1 million in share-based compensation expense related to options vested to date.

On August 4, 2016, Company issued a warrant to purchase 1,500,000 shares of the Company's common stock at the price of $0.36 per share to Pacific Leaf and its designees and recorded a related expense of $0.5 million. The warrant to purchase common shares was issued to satisfy the conditions under the Second Omnibus Amendment described in detail in Note 4 to the financial statements for the nine months ended December 31, 2016.

On November 7, 2016, the Company received a notice that the Noteholder had elected to convert $300,000 of the Company's indebtedness into common stock of the Company pursuant to the Short-Term Convertible Note Agreement.  Accordingly, the Company issued 1,500,000 shares of its common stock ($300,000 converted at a price of $0.20 per share) and a warrant to purchase 1,500,000 shares of the Company's common stock at the price of $0.50 per share for the period of three years.  As a result of the conversion, the Company recorded a loss of $0.1 million.
During the nine months ended December 31, 2016, the Company issued a compensation warrant to purchase 1,912,500 shares of the Company's common stock pursuant to the terms of a private placement agreement. The warrant is exercisable at the price of $0.50 per share for the period of three years. As a result of this issuance, the Company recorded compensation expense of $0.9 million.
During the nine months ended December 31, 2016, the Company issued a compensation warrant to purchase 1,500,000 shares of the Company's common stock pursuant to the terms of a private placement agreement. The warrant is exercisable at the price of $0.60 per share for the period of five years. As a result of this issuance, the Company recorded compensation expense of $0.4 million.
All of the foregoing securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933 (the " Securities Act ") and/or Rule 506 of Regulation D under the Securities Act, as amended.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not Applicable.

ITEM 5. Other Information

None.
ITEM 6. Exhibits
In reviewing the agreements included as exhibits to this Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:
·
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
·
have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
·
may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and
·
were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.
Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Form 10-Q and the Company's other public filings, which are available without charge through the SEC's website at http://www.sec.gov.
The following exhibits are included as part of this report:
Exhibit Number
 
Description of Exhibit
3.1
 
Articles of Incorporation ( Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)
3.2
 
Amendment to Articles of Incorporation ( Incorporated by reference to Exhibit 3.2 to Form S-1/A No. 333-82580 filed with the Commission on October 6, 2014 and Exhibit 3.2 to Form 10-K No. 333-82580 filed with the Commission on June 27, 2014 )
3.3
 
Bylaws ( Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002 )
31.1
 
Certification of Principal Executive Officer and Pursuant to Rule 13a-14
31.2
 
Certification of Principal Financial Officer Pursuant to Rule 13a-14
32.1*
 
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2*
 
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
* This certification is being furnished and shall not be deemed "filed" with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
GROWBLOX SCIENCES, INC.
 
 
February 14, 2017
By:
/s/ John Poss
 
John Poss, Chief Executive Officer (Principal Executive Officer)
 
 
 
GROWBLOX SCIENCES, INC.
 
 
February 14, 2017
By:
/s/ Ksenia Griswold
 
Ksenia Griswold, Chief Financial Officer (Principal Financial Officer)
 
 

21

GB Sciences, Inc. (USOTC:GBLX)
Historical Stock Chart

1 Year : From Aug 2016 to Aug 2017

Click Here for more GB Sciences, Inc. Charts.

GB Sciences, Inc. (USOTC:GBLX)
Intraday Stock Chart

Today : Thursday 17 August 2017

Click Here for more GB Sciences, Inc. Charts.

Latest GBLX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.